Literature DB >> 26476499

Natriuretic peptides for perioperative management of cardiac surgery.

Akira Sezai1, Motomi Shiono2.   

Abstract

Atrial natriuretic peptide (carperitide) is used to treat heart failure in Japan, while brain natriuretic peptide (nesiritide) is employed in Europe/USA. Patients undergoing cardiac surgery have a complex underlying pathologic state that features increased levels of neurohumoral factors due to activation of the renin-angiotensin-aldosterone system and/or increased sympathetic activity. We considered that perioperative administration of carperitide could be beneficial for cardiac surgery patients, and we have conducted clinical investigations of its use. This article reviews the effects of natriuretic peptides in cardiac surgery patients based on our experience and on previous reports about perioperative management with carperitide or nesiritide.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  Atrial natriuretic peptide; Cardiac surgery; Natriuretic peptide; Postoperative management

Mesh:

Substances:

Year:  2015        PMID: 26476499     DOI: 10.1016/j.jjcc.2015.09.011

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  3 in total

1.  Effect of carperitide on in-hospital mortality of patients admitted for heart failure: propensity score analyses.

Authors:  Masataka Ogiso; Toshiaki Isogai; Yuta Okabe; Kansuke Ito; Masaki Tsuji; Hiroyuki Tanaka
Journal:  Heart Vessels       Date:  2017-02-20       Impact factor: 2.037

2.  Effect of recombinant human brain natriuretic peptide on acute kidney injury after coronary artery bypass grafting: a retrospective comparative cohort study.

Authors:  Ziyao Wang; Yangyan Wei; Junyu Chen; Qian Zhang; Jiwen Tang; Qing Chang
Journal:  Ann Transl Med       Date:  2022-09

3.  N-Terminal of the Prohormone Brain Natriuretic Peptide Predicts Postoperative Cardiogenic Shock Requiring Extracorporeal Membrane Oxygenation.

Authors:  Piotr Duchnowski
Journal:  J Clin Med       Date:  2022-09-20       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.